Raymond James & Associates Humacyte, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Humacyte, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 43,278 shares of HUMA stock, worth $198,213. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,278Holding current value
$198,213% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HUMA
# of Institutions
149Shares Held
35.1MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$32.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$23.2 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$21.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9.34 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.81 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $472M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...